New cocktail of three drugs tested for tough bladder cancers
NCT ID NCT01352962
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 12 times
Summary
This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the safest dose and see how well patients tolerated the treatment. Participants received up to six cycles of the three-drug combo, and some continued lenalidomide alone for up to a year if their cancer did not grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gemcitabine, carboplatin, and lenalidomide
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for advanced urothelial cancer and other solid tumors that have not responded to standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 18 participants, focused on finding the safest dose. The combination may cause severe side effects, and it is unknown whether it will actually shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- MRI screening may spot pancreatic cancer sooner in High-Risk gene carriers
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?